Seven Fleet Capital Portfolio Shifts in Q2 2026

Active Position Adjustments

This quarter has seen significant activity from Seven Fleet Capital Management Lp, with substantial changes in its portfolio composition. The investor's holdings have undergone considerable shifts, reflecting strategic decisions to buy and sell positions.

Significant Purchases

CG ONCOLOGY INC (CGON) stands out as a major purchase, increasing its stake by 1810478 shares or an impressive 2389.82% quarter-on-quarter, now representing 22.12% of the portfolio value.

TANGO THERAPEUTICS INC (TNGX) also saw a massive increase in its position, with 2726132 shares added at a change percentage of 543.04%, now holding 15.79%.

Revolution Medicines Inc (RVMD), Avalo Therapeutics Inc (AVTX), and Editas Medicine Inc (EDIT) were other significant additions, although their allocations are currently smaller (7.48%, 2.35%, and 0.71% respectively).

Sector Focus Remains on Healthcare

The bulk of the portfolio, 93.4%, is allocated to the Healthcare sector as of June 30th, 2026.

This allocation includes a wide array of companies focused on drug development and therapeutics, such as CGON, TNGX, RVMD, PHVS (which has an unusually high change percentage but no sector assigned), ELVN, ABVX, AVTX, MIRM, ASMB, IPSC, EDIT, CTMX, NERV, GERN, SABS, SGMT, and CTCM.

The continued focus on this sector suggests confidence in the long-term prospects of healthcare innovation. The specific purchases mentioned above further indicate an interest in certain segments within this broad category.

Notable Sales

In contrast to its buying activity, Seven Fleet Capital also divested some positions during the quarter.

The most significant sale was CENTURY THERAPEUTICS INC (IPSC), which saw a decrease of 1400000 shares or 47.49% from its previous position, now accounting for just 1.76% of the portfolio.

Sab Biotherapeutics Inc (SABS), Taysha Gene Therapies Inc (TSHA), and C4 Therapeutics Inc (CCCC) also experienced notable reductions, although their current allocations are minimal (0.47%, 1.64%, and 0.29% respectively).

Significant Exits

The investor's filing indicates exits from other positions, including Avalo Therapeutics Inc (AVTX), which was sold entirely out of the portfolio.

Sab Biotherapeutics Inc (SABS) and C4 Therapeutics Inc (CCCC) also appear to have been completely divested based on their zero current allocation percentages, despite being listed in changed_holdings as having share changes.

Overall Portfolio Dynamics

The portfolio currently holds 74 distinct positions (Seven Fleet Capital). The top five holdings by weight account for a combined 53.18% of the total value, highlighting concentration in these key stocks.